Immunology

Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis



http://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/2fe5e828-8077-41f9-addf-0eb797a53b96/fx1.jpg

  • Quality of life in patients with chronic rhinosinusitis.

    Curr Allergy Asthma Rep. 2011; 11: 247-252

    • Schlosser R.J.
    • Gage S.E.
    • Kohli P.
    • Soler Z.M.

    Burden of illness: a systematic review of depression in chronic rhinosinusitis.

    Am J Rhinol Allergy. 2016; 30: 250-256

    • Johansson L.
    • Akerlund A.
    • Holmberg K.
    • Melen I.
    • Bende M.

    Prevalence of nasal polyps in adults: the Skovde population-based study.

    Ann Otol Rhinol Laryngol. 2003; 112: 625-629

    • Klossek J.M.
    • Neukirch F.
    • Pribil C.
    • Jankowski R.
    • Serrano E.
    • Chanal I.
    • et al.

    Prevalence of nasal polyposis in France: a cross-sectional, case–control study.

    Allergy. 2005; 60: 233-237

    • Chen S.
    • Zhou A.
    • Emmanuel B.
    • Thomas K.
    • Guiang H.

    Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.

    Curr Med Res Opin. 2020; 36: 1897-1911

    • Rajan J.P.
    • Wineinger N.E.
    • Stevenson D.D.
    • White A.A.

    Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature.

    J Allergy Clin Immunol. 2015; 135: 676-681.e1

    • Peters A.T.
    • Spector S.
    • Hsu J.
    • Hamilos D.L.
    • Baroody F.M.
    • Chandra R.K.
    • et al.

    Diagnosis and management of rhinosinusitis: a practice parameter update.

    Ann Allergy Asthma Immunol. 2014; 113: 347-385

    • Fokkens W.J.
    • Lund V.J.
    • Hopkins C.
    • Hellings P.W.
    • Kern R.
    • Reitsma S.
    • et al.

    European position paper on rhinosinusitis and nasal polyps, 2020.

    Rhinology. 2020; 58: 1-464

    • Bachert C.
    • Marple B.
    • Hosemann W.
    • Cavaliere C.
    • Wen W.
    • Zhang N.

    Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications.

    J Allergy Clin Immunol Pract. 2020; 8: 1514-1519

    • Wang X.
    • Zhang N.
    • Bo M.
    • Holtappels G.
    • Zheng M.
    • Lou H.
    • et al.

    Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania.

    J Allergy Clin Immunol. 2016; 138: 1344-1353

    • Iqbal I.Z.
    • Kao S.S.
    • Ooi E.H.

    The role of biologics in chronic rhinosinusitis: a systematic review.

    Int Forum Allergy Rhinol. 2020; 10: 165-174

    • Chong L.Y.
    • Piromchai P.
    • Sharp S.
    • Snidvongs K.
    • Philpott C.
    • Hopkins C.
    • et al.

    Biologics for chronic rhinosinusitis.

    Cochrane Database Syst Rev. 2020; 2CD013513

    • Agache I.
    • Song Y.
    • Alonso-Coello P.
    • Vogel Y.
    • Rocha C.
    • Solà I.
    • et al.

    Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines.

    Allergy. 2021; 76: 2337-2353

    • Peters A.T.
    • Han J.K.
    • Hellings P.
    • Heffler E.
    • Gevaert P.
    • Bachert C.
    • et al.

    Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps.

    J Allergy Clin Immunol Pract. 2021; 9: 2461-2471.e5

  • Aspirin desensitization vs biologics for patients with aspirin-exacerbated respiratory disease.

    Ann Allergy Asthma Immunol. 2021; 126: 118-119

  • Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions, version 6.2 (updated February 2021). Cochrane, 2021. Available at: http://www.training.cochrane.org/handbook. Accessed September 20, 2021.

    • Guyatt G.H.
    • Oxman A.D.
    • Vist G.E.
    • Kunz R.
    • Falck-Ytter Y.
    • Alonso-Coello P.
    • et al.

    GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

    BMJ. 2008; 336: 924-926

    • Liberati A.
    • Altman D.G.
    • Tetzlaff J.
    • Mulrow C.
    • Gotzsche P.C.
    • Ioannidis J.P.
    • et al.

    The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

    J Clin Epidemiol. 2009; 62: e1-e34

    • Hutton B.
    • Salanti G.
    • Caldwell D.M.
    • Chaimani A.
    • Schmid C.H.
    • Cameron C.
    • et al.

    The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.

    Ann Intern Med. 2015; 162: 777-784

    • Chu D.K.
    • Lee D.J.
    • Lee K.M.
    • Schünemann H.J.
    • Szczeklik W.
    • Lee J.M.

    Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis.

    Int Forum Allergy Rhinol. 2019; 9: 1409-1419

    • Sterne J.A.C.
    • Savovic J.
    • Page M.J.
    • Elbers R.G.
    • Blencowe N.S.
    • Boutron I.
    • et al.

    RoB 2: a revised tool for assessing risk of bias in randomised trials.

    BMJ. 2019; 366: l4898

    • Siemieniuk R.A.
    • Bartoszko J.J.
    • Ge L.
    • Zeraatkar D.
    • Izcovich A.
    • Kum E.
    • et al.

    Drug treatments for Covid-19: living systematic review and network meta-analysis.

    BMJ. 2020; 370: m2980

    • Brignardello-Petersen R.
    • Murad M.H.
    • Walter S.D.
    • McLeod S.
    • Carrasco-Labra A.
    • Rochwerg B.
    • et al.

    GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks.

    J Clin Epidemiol. 2019; 105: 60-67

    • Brignardello-Petersen R.
    • Florez I.D.
    • Izcovich A.
    • Santesso N.
    • Hazlewood G.
    • Alhazanni W.
    • et al.

    GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework.

    BMJ. 2020; 371m3900

    • Thorlund K.
    • Walter S.D.
    • Johnston B.C.
    • Furukawa T.A.
    • Guyatt G.H.

    Pooling health-related quality of life outcomes in meta-analysis—a tutorial and review of methods for enhancing interpretability.

    Res Synth Methods. 2011; 2: 188-203

    • Schandelmaier S.
    • Briel M.
    • Varadhan R.
    • Schmid C.H.
    • Devasenapathy N.
    • Hayward R.A.
    • et al.

    Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.

    CMAJ. 2020; 192: E901-E906

    • Ebrahim S.
    • Akl E.A.
    • Mustafa R.A.
    • Sun X.
    • Walter S.D.
    • Heels-Ansdell D.
    • et al.

    Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers.

    J Clin Epidemiol. 2013; 66: 1014-1021.e1

    • Akl E.A.
    • Johnston B.C.
    • Alonso-Coello P.
    • Neumann I.
    • Ebrahim S.
    • Briel M.
    • et al.

    Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers.

    PLoS One. 2013; 8e57132

  • Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available at: https://gdt.gradepro.org/app/handbook/handbook.html. Accessed September 20, 2021.

    • Santesso N.
    • Glenton C.
    • Dahm P.
    • Garner P.
    • Akl E.A.
    • Alper B.
    • et al.

    GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions.

    J Clin Epidemiol. 2020; 119: 126-135

  • Reslizumab an interleukin-5 antagonist monoclonal antibody for uncontrolled chronic rhinosinusitis with nasal polyps.

    Ann Allergy Asthma Immunol. 2020; 125: S49-S50

  • Efficacy of subcutaneous dupilumab a human anti–interleukin-4 receptor alpha monoclonal antibody for moderate-to-severe uncontrolled asthmatics.

    Ann Allergy Asthma Immunol. 2018; 121: S40-S41

    • Mostafa B.E.
    • Fadel M.
    • Mohammed M.A.
    • Hamdi T.A.H.
    • Askoura A.M.

    Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis.

    Eur Arch Otorhinolaryngol. 2020; 277: 121-128

    • Pinto J.M.
    • Mehta N.
    • DiTineo M.
    • Wang J.
    • Baroody F.M.
    • Naclerio R.M.

    A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis.

    Rhinology. 2010; 48: 318-324

    • Gevaert P.
    • Calus L.
    • Van Zele T.
    • Blomme K.
    • De Ruyck N.
    • Bauters W.
    • et al.

    Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

    J Allergy Clin Immunol. 2013; 131: 110-116.e1

    • Hayashi H.
    • Fukutomi Y.
    • Mitsui C.
    • Kajiwara K.
    • Watai K.
    • Kamide Y.
    • et al.

    Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial.

    Am J Respir Crit Care Med. 2020; 201: 1488-1498

    • Wahba A.A.
    • Abdelfattah A.M.

    Anti–immunoglobulin E therapy: is it a valid option for the management of chronic rhinosinusitis with nasal polyposis?.

    Egypt J Otolaryngol. 2019; 35: 269-277

    • Gevaert P.
    • Omachi T.A.
    • Corren J.
    • Mullol J.
    • Han J.
    • Lee S.E.
    • et al.

    Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.

    J Allergy Clin Immunol. 2020; 146: 595-605

    • Nelsen L.
    • Bradford E.S.
    • Bratton D.J.
    • Albers F.C.
    • Brusselle G.

    Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma.

    Eur Respir J. 2017; 50 ()

    • Bachert C.
    • Sousa A.R.
    • Lund V.J.
    • Scadding G.K.
    • Gevaert P.
    • Nasser S.
    • et al.

    Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial.

    J Allergy Clin Immunol. 2017; 140: 1024-1031.e14

    • Gevaert P.
    • Van Bruaene N.
    • Cattaert T.
    • Van Steen K.
    • Van Zele T.
    • Acke F.
    • et al.

    Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis.

    J Allergy Clin Immunol. 2011; 128: 989-995.e1-8

    • Gevaert P.
    • Van Bruaene N.
    • Blomme K.
    • Sousa A.R.
    • Marshal R.P.
    • Bachert C.

    Mepolizumab, a humanised anti–IL-5 monoclonal antibody, as treatment of severe nasal polyposis.

    J Allergy Clin Immunol. 2008; 121 ()

    • Bachert C.
    • Sousa A.
    • Han J.
    • Schlosser R.
    • Sowerby L.
    • Hopkins C.
    • et al.

    Mepolizumab for chronic rhinosinusitis with nasal polyps: comorbid asthma, NSAID exacerbated respiratory disease, eosinophil stratification.

    Ann Allergy Asthma Immunol. 2020; 125: S47

    • Chupp G.L.
    • Bradford E.S.
    • Albers F.C.
    • Bratton D.J.
    • Wang-Jairaj J.
    • Nelsen L.M.
    • et al.

    Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.

    Lancet Respir Med. 2017; 5: 390-400

    • Lee S.
    • Tabberer M.
    • Trigg A.
    • Han J.
    • Fokkens W.
    • Naclerio R.
    • et al.

    Mepolizumab improves health related quality of life for patients with chronic rhinosinusitis with nasal polyps: data from the SYNAPSE study.

    J Allergy Clinical Immunol. 2021; 147: AB125

    • Gevaert P.
    • Lang-Loidolt D.
    • Lackner A.
    • Stammberger H.
    • Staudinger H.
    • Van Zele T.
    • et al.

    Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polyps.

    J Allergy Clin Immunol. 2006; 118: 1133-1141

    • Castro M.
    • Mathur S.
    • Hargreave F.
    • Boulet L.P.
    • Xie F.
    • Young J.
    • et al.

    Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.

    Am J Respir Crit Care Med. 2011; 184: 1125-1132

    • Esmaeilzadeh H.
    • Nabavi M.
    • Aryan Z.
    • Arshi S.
    • Bemanian M.H.
    • Fallahpour M.
    • et al.

    Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a randomized double-blind placebo-controlled trial.

    Clin Immunol. 2015; 160: 349-357

    • Fruth K.
    • Pogorzelski B.
    • Schmidtmann I.
    • Springer J.
    • Fennan N.
    • Fraessdorf N.
    • et al.

    Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease.

    Allergy. 2013; 68: 659-665

    • Mortazavi N.
    • Esmaeilzadeh H.
    • Abbasinazari M.
    • Babaie D.
    • Alyasin S.
    • Nabavizadeh H.
    • et al.

    Clinical and immunological efficacy of aspirin desensitization in nasal polyp patients with aspirin-exacerbated respiratory disease.

    Iran J Pharm Res. 2017; 16: 1639-1647

    • Stevenson D.D.
    • Pleskow W.W.
    • Simon R.A.
    • Mathison D.A.
    • Lumry W.R.
    • Schatz M.
    • et al.

    Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin.

    J Allergy Clin Immunol. 1984; 73: 500-507

    • Swierczynska-Krepa M.
    • Sanak M.
    • Bochenek G.
    • Strek P.
    • Cmiel A.
    • Gielicz A.
    • et al.

    Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.

    J Allergy Clin Immunol. 2014; 134: 883-890

    • Han J.K.
    • Bachert C.
    • Fokkens W.
    • Desrosiers M.
    • Wagenmann M.
    • Lee S.E.
    • et al.

    Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Lancet Respir Med. 2021; 9: 1141-1153

    • Tversky J.
    • Lane A.P.
    • Azar A.

    Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial.

    Clin Exp Allergy. 2021; 51: 836-844

    • Castro M.
    • Corren J.
    • Pavord I.D.
    • Maspero J.
    • Wenzel S.
    • Rabe K.F.
    • et al.

    Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma.

    N Engl J Med. 2018; 378: 2486-2496

    • Busse W.
    • Maspero J.F.
    • Katelaris C.H.
    • Saralaya D.
    • Guillonneau S.
    • Zhang B.
    • et al.

    Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in liberty asthma quest.

    Eur Respir J. 2018; 52 ()

  • Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. In press.

    • Harrison T.W.
    • Chanez P.
    • Menzella F.
    • Canonica G.W.
    • Louis R.
    • Cosio B.G.
    • et al.

    Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.

    Lancet Respir Med. 2021; 9: 260-274

    • Mullol J.
    • Laidlaw T.M.
    • Dong Q.
    • Fan C.
    • Zhang D.
    • Amin N.
    • et al.

    Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and NSAID-ERD.

    Allergy Eur J Allergy Clin Immunol. 2018; 73: 203

    • Laidlaw T.M.
    • Mullol J.
    • Fan C.
    • Zhang D.
    • Amin N.
    • Khan A.
    • et al.

    Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.

    J Allergy Clin Immunol In Practice. 2019; 7: 2462-2465.e1

    • Mullol J.
    • Laidlaw T.M.
    • Amin N.
    • Bachert C.
    • Han J.K.
    • Hellings P.W.
    • et al.

    Dupilumab (DPL) efficacy in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) with/without nonsteroidal anti-inflammatory drug–exacerbated respiratory disease (NSAID-ERD): SINUS-24, SINUS-52 trials.

    Eur Respir J. 2019; 54 ()

    • Bachert C.
    • Mannent L.
    • Naclerio R.M.
    • Mullol J.
    • Ferguson B.J.
    • Gevaert P.
    • et al.

    Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial.

    JAMA. 2016; 315: 469-479

  • Phenotypes and emerging endotypes of chronic rhinosinusitis.

    J Allergy Clin Immunol Pract. 2016; 4: 621-628

    • Chu D.K.
    • Llop-Guevara A.
    • Walker T.D.
    • Flader K.
    • Goncharova S.
    • Boudreau J.E.
    • et al.

    IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization.

    J Allergy Clin Immunol. 2013; 131: 187-200.e1-8

    • Wilkes S.R.
    • Nankervis H.
    • Tavernier E.
    • Maruani A.
    • Williams H.C.

    How clinically relevant are treatment comparisons of topical calcineurin inhibitor trials for atopic eczema?.

    J Invest Dermatol. 2016; 136: 1944-1949

    • Lang D.M.
    • Aronica M.A.
    • Maierson E.S.
    • Wang X.F.
    • Vasas D.C.
    • Hazen S.L.

    Omalizumab can inhibit respiratory reaction during aspirin desensitization.

    Ann Allergy Asthma Immunol. 2018; 121: 98-104

  • Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: a review of preliminary data, efficacy, and cost.

    World J Otorhinolaryngol Head Neck Surg. 2020; 6: 230-234

    • Bachert C.
    • Han J.K.
    • Desrosiers M.
    • Hellings P.W.
    • Amin N.
    • Lee S.E.
    • et al.

    Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.

    Lancet. 2019; 394: 1638-1650

    • Rabe K.F.
    • Nair P.
    • Brusselle G.
    • Maspero J.F.
    • Castro M.
    • Sher L.
    • et al.

    Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

    N Engl J Med. 2018; 378: 2475-2485

    • Takabayashi T.
    • Asaka D.
    • Okamoto Y.
    • Himi T.
    • Haruna S.
    • Yoshida N.
    • et al.

    A Phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis.

    Am J Rhinol Allergy. 2021; https://doi.org/10.1177/19458924211009429

    • Laidlaw T.M.
    • Bachert C.
    • Amin N.
    • Desrosiers M.
    • Hellings P.W.
    • Mullol J.
    • et al.

    Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.

    Ann Allergy Asthma Immunol. 2021; 126: 584-92 e1



  • Source link

    Products You May Like

    Articles You May Like

    A specific bacteria-infecting virus, bacteriophage, found in gut microflora, augments anti-tumor T cell immunity
    Supreme Court to hear 340B case that could impact all hospitals
    Overactive WASp in X-linked neutropenia leads to aberrant B-cell division and accelerated plasma cell generation
    Bronchial thermoplasty: The heat that reprograms the airways?
    Inducible expression quantitative trait locus analysis of the MUC5AC gene in asthma in urban populations of children

    Leave a Reply

    Your email address will not be published. Required fields are marked *